Raymond James Upgrades InflaRx to Strong Buy, Raises Price Target to $9

InflaRx

InflaRx

IFRX

0.00

Raymond James analyst Ryan Deschner upgrades InflaRx (NASDAQ: IFRX) from Outperform to Strong Buy and raises the price target from $7 to $9.